Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2019 Sep;31(9):637-645.
doi: 10.1016/j.clon.2019.04.009. Epub 2019 May 20.

Radiotherapy Management of Muscle Invasive Bladder Cancer: Evaluation of a National Cohort

M Varughese  1 , S Treece  2 , K J Drinkwater  3
Affiliations
Multicenter Study

Radiotherapy Management of Muscle Invasive Bladder Cancer: Evaluation of a National Cohort

M Varughese et al. Clin Oncol (R Coll Radiol). 2019 Sep.

Abstract

Aims: With the failure to improve outcomes of patients with bladder cancer over the last 30 years, this study was developed to benchmark contemporary UK radiotherapy practice for the management of muscle invasive bladder cancer (MIBC) against published national guidance.

Materials and methods: All UK radiotherapy centres were invited to complete a questionnaire for each patient with MIBC starting bladder radiotherapy over a 16-week period from December 2016.

Results: Sixty-nine per cent (41/59) of UK radiotherapy centres completed a detailed questionnaire for 508 patients. The median age was 78 years and 64% (n = 323 patients) had stage II or III disease. Treatment intent was radical in 54% (n = 275). From transurethral resection of the bladder tumour, patients waited 57 days before starting neoadjuvant chemotherapy (NAC) (interquartile range 46-72 days). Patients who had radical radiotherapy as their first definitive treatment waited a median of 82 days (interquartile range 62-105 days). NAC was considered in 66% (n = 182) of all radical cases and given in 43% (n = 119). Concurrent radiosensitisation (CRT) was considered for 53% (n = 146) and delivered in 40% (n = 109) of patients. The most common fractionation was 55 Gy/20 fractions/4 weeks in 49% (n = 134) for radical patients and 36 Gy/6 fractions/6 weeks in 25% (n = 57) for palliative patients.

Conclusion: This is the largest multicentre prospective study to define contemporary management of MIBC in patients receiving radiotherapy within the UK. The population studied is the oldest described to date. Timelines to starting definitive treatment confirm an urgent need to streamline the pathway. An increasing use of NAC is described, although the penetrance of CRT is disappointingly low. Areas for improvement with regards to the delivery and quality of radiotherapy have been identified. The detail within this study can be used to inform practice and future trial design, ultimately with the aim of improving outcomes for patients with MIBC.

Keywords: Concurrent radio sensitisation; MIBC; muscle invasive bladder cancer; national cohort; neo-adjuvant chemotherapy; radiotherapy.

PubMed Disclaimer

Publication types